Medicamentos para Obesidade e Diabetes: Estudo Massivo Aponta Promessa no Combate a Vícios e Redução do Risco de Morte

Injections that reduce weight and treat diabetes could also cut the risk of dying from substance-use disorders.Credit: Jill Connelly/Bloomberg/Getty Blockbuster GLP-1 medications might help people to avoid becoming addicted to drugs, including alcohol, cocaine and opioids, a massive study1 suggests. It also found that, for those already dealing with addiction, the treatments are linked to a 50% reduction in the risk of dying from substance abuse. The findings, published today in The BMJ, come from an analysis of electronic health records from more than 600,000 people in the database of the US Department of Veterans Affairs (VA), which provides care for millions of military veterans. The study is the latest suggesting that GLP-1 drugs — which mimic a hormone called glucagon-like peptide 1 and are mainly prescribed to treat obesity and type 2 diabetes — can also play a part in curbing addiction. Why do obesity drugs seem to treat so many other ailments? The study’s large number of participants is unique and allowed researchers to evaluate the effect of GLP-1 drugs on the risk of several substance-use disorders. “The consistency of effect across multiple substances, which have different mechanisms of action, was quite a revelation,” says Ziyad Al-Aly, a co-author and a clinical epidemiologist the VA St Louis Health Care System in Missouri. The observational study confirms what physicians are seeing in their clinics and the results of some small clinical trials2. But larger clinical trials are still needed to demonstrate whether the drugs could truly help people with substance-use disorders, specialists say. “We have our patients telling us, ‘I don’t feel like I want to smoke anymore. I don’t really have the interest in drinking anymore,’” says Daniel Drucker, an endocrinologist at the University of Toronto in Canada. “There’s no question this is real and there are responders. But, so far, we don’t have a really robust, randomized, controlled clinical trial.” Intrigued by peoples’ reports of reduced alcohol cravings while taking GLP-1 drugs, Al-Aly turned to the VA’s database of electronic health records. “It’s a colossal data system and it creates a great opportunity,” he says. Al-Aly and his colleagues used the database to compare two groups of people with type 2 diabetes: the treatment group, which had been prescribed GLP-1 drugs, and the control group, which had been prescribed a different class of diabetes medication, called sodium-glucose cotransporter-2 (SGLT-2). They were followed for up to three years after they began taking either medication. Anti-obesity drug has life-changing benefits for arthritis Among the GLP-1 users with no history of addiction, the risk of developing a substance-use disorder over the three-year period was 18% lower for alcohol, 14% lower for cannabis, 20% lower for cocaine, 20% lower for nicotine and 25% lower for opioids than among those in the control group. doi: https://doi.org/10.1038/d41586-026-00734-2 Cai, M., Choi, T., Xie, Y. & Al-Aly, Z. BMJ 392, e086886 (2026). Article  Google Scholar Hendershot, C. S. et al. JAMA Psych. 82, 395–405 (2026). Reprints and permissions Obesity drugs: huge study identifies new health risks How rival weight-loss drugs fare at treating obesity, diabetes and more Will blockbuster obesity drugs revolutionize addiction treatment? Are obesity drugs causing a severe complication? What the science says News Explainer 20 FEB 26 The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs News Feature 02 DEC 25 Cancer blood tests are everywhere. Do they really work? News Feature 04 MAR 26 Magnetic fluid offers better seal in heart-plugging medical procedure News & Views 04 MAR 26 Skin cells boost distant antibody responses A foundation model for continuous glucose monitoring data Job Title:    Deputy Editor, Communications Medicine Location:    Shanghai, Beijing, Hybrid Working Model Application Deadline: Mar 26th, 2026   Ab... Shanghai, Beijing, Hybrid Working Model Seeking exceptional Senior/Junior PIs, Postdocs, and Core Specialists globally year-round Hangzhou Institute of Medicine Chinese Academy of Sciences (HIMCAS) Join HZAU's global faculty team to advance research with competitive benefits. No.1 Shizishan Street, Hongshan District, Wuhan, Hubei Province, China Huazhong Agricultural University (HZAU) Postdoctoral fellow positions are available Robert Wood Johnson Medical School - Department of Neurosurgery The Medical Faculty Mannheim of Heidelberg University offers the position of a   Full professorship (W3) for “Transfusion Medicine and Immunology” ... Mannheim, Baden-Württemberg (DE) Medizinische Fakultät Mannheim der Universität Heidelberg Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily. Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.